LEARNING PROGRAM REGISTRATION

BACK About the Program

Join Dr. Jonathan Silverberg for an engaging accredited evening featuring international expertise and real world clinical perspectives on the management of moderate-to-severe atopic dermatitis. Interactive sessions pair self‑assessment with expert insights on AD treatments, IL‑13 pathways, and biologic differentiation, plus personalized feedback to support improved patient outcomes.

Program Learning Objectives

  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making

May 25th, 2026

Arrival
6:30 pm EDT
Presentation Start
7:00 pm EDT
Presentation End
8:30 pm EDT
Add to Calendar 05/25/2026 07:00 pm 05/25/2026 08:30 pm America/Toronto Cross-Border Perspectives in Atopic Dermatitis

Thank you for your interest in the presentation of the program titled Cross-Border Perspectives in Atopic Dermatitis.

SPEAKER: Jonathan Silverberg, MD, PhD, MPH, FAAD
MODERATOR: Catherine Maari, MD, FRCPC

LOCATION:
Hôtel Le Germain Montreal, 2050 Rue Mansfield, Montreal, QC, H3A 1Y9

Learning Objectives:
Upon completion of this program, participants will be better able to:
  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making
This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.

You will receive a reminder by email in the days prior to the event.

For any questions related to this in person, please contact implementation@livagency.ca.

 Hôtel Le Germain Montreal 2050 Rue Mansfield Montreal, QC H3A 1Y9

Hôtel Le Germain Montreal
2050 Rue Mansfield
Montreal, QC H3A 1Y9

Speaker(s) Jonathan Silverberg, MD, PhD, MPH, FAAD
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Moderator(s) Catherine Maari, MD, FRCPC
Associate clinical professor, Department of Medicine, Université de Montréal
Centre hospitalier de l’Université de Montréal (CHUM)
CHU Sainte-Justine
Montreal, QC



This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.